Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Maura Brioschi, Alma Martinez Fernandez & Cristina Banfi. (2017) Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential. Expert Review of Proteomics 14:6, pages 515-528.
Read now
Read now
Heinz Reichmann & Murat Emre. (2012) Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone. Expert Review of Neurotherapeutics 12:2, pages 119-131.
Read now
Read now
Articles from other publishers (10)
P. Sivakumar, K.B. Nagashanmugam, S. Priyatharshni, R. Lavanya, N. Prabhu & S. Ponnusamy. (2023) Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease. Neurochemistry International 162, pages 105461.
Crossref
Crossref
T. Sengupta, J. Vinayagam, R. Singh, P. Jaisankar & K. P. Mohanakumar. 2016. The Benefits of Natural Products for Neurodegenerative Diseases. The Benefits of Natural Products for Neurodegenerative Diseases
415
496
.
Paul Bishop, Philip Rubin, Andrew R. Thomson, Dan Rocca & Jeremy M. Henley. (2014) The Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) C Terminus Plays a Key Role in Protein Stability, but Its Farnesylation Is Not Required for Membrane Association in Primary Neurons. Journal of Biological Chemistry 289:52, pages 36140-36149.
Crossref
Crossref
Anna Kaplan & Brent R. Stockwell. (2012) Therapeutic approaches to preventing cell death in Huntington disease. Progress in Neurobiology 99:3, pages 262-280.
Crossref
Crossref
Ronald B. Postuma, Jean-Francois Gagnon & Jacques Y. Montplaisir. (2012) REM sleep behavior disorder: From dreams to neurodegeneration. Neurobiology of Disease 46:3, pages 553-558.
Crossref
Crossref
Melanie Gerard, Angélique Deleersnijder, Jonas Demeulemeester, Zeger Debyser & Veerle Baekelandt. (2011) Unraveling the Role of Peptidyl-Prolyl Isomerases in Neurodegeneration. Molecular Neurobiology 44:1, pages 13-27.
Crossref
Crossref
Peter A LeWitt, Ali R Rezai, Maureen A Leehey, Steven G Ojemann, Alice W Flaherty, Emad N Eskandar, Sandra K Kostyk, Karen Thomas, Atom Sarkar, Mustafa S Siddiqui, Stephen B Tatter, Jason M Schwalb, Kathleen L Poston, Jaimie M Henderson, Roger M Kurlan, Irene H Richard, Lori Van Meter, Christine V Sapan, Matthew J During, Michael G Kaplitt & Andrew Feigin. (2011) AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet Neurology 10:4, pages 309-319.
Crossref
Crossref
Mark J. Millan. (2010) From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacology & Therapeutics 128:2, pages 229-273.
Crossref
Crossref
Saviana Di Giovanni, Simona Eleuteri, Katerina E. Paleologou, Guowei Yin, Markus Zweckstetter, Pierre-Alain Carrupt & Hilal A. Lashuel. (2010) Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity. Journal of Biological Chemistry 285:20, pages 14941-14954.
Crossref
Crossref
Melanie Gerard, Angélique Deleersnijder, Veronique Daniëls, Sarah Schreurs, Sebastian Munck, Veerle Reumers, Hans Pottel, Yves Engelborghs, Chris Van den Haute, Jean-Marc Taymans, Zeger Debyser & Veerle Baekelandt. (2010) Inhibition of FK506 Binding Proteins Reduces α-Synuclein Aggregation and Parkinson's Disease-Like Pathology. The Journal of Neuroscience 30:7, pages 2454-2463.
Crossref
Crossref